DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes

DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes

imedex

11 months
93 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Earn CME: https://naccme.com/program/7312 In this presentation from the 'Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. C. Ola Landgren argues that MRS is new primary goal for multiple myeloma treatment. © 2018 Imedex, an HMP Company
Up Next Autoplay
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
0 Views
Cancer-News 6 minutes
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
0 Views
Cleveland Clinic 23 minutes
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
1 Views
Cleveland Clinic 37 minutes
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
Category: News
2 Views
alexvarney 1 hour
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 15 hours
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Category: News
3 Views
alexvarney 21 hours
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 22 hours
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
39 Views
kidneycancer 1 day
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
11 Views
UVA Cancer Center 1 day
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 2 days